Chronic granulomatous disease: Difference between revisions

From IDWiki
()
m (Text replacement - " species]]" to "]]")
 
(2 intermediate revisions by the same user not shown)
Line 11: Line 11:


*Recurrent infections
*Recurrent infections
**Catalase-positive organisms, including [[Staphylococcus aureus]], [[Burkholderia cepacia]], [[Serratia marcescens]], [[Nocardia species]], and [[Aspergillus species]]
**Catalase-positive organisms, including [[Staphylococcus aureus]], [[Burkholderia cepacia]], [[Serratia marcescens]], [[Nocardia]], and [[Aspergillus]]
**CGD is the highest-risk group for [[invasive aspergillosis]]
**CGD is the highest-risk group for [[invasive aspergillosis]]
*Granuloma formation, often in the GI and GU tracts and may precede other clinical symptoms
*Granuloma formation, often in the GI and GU tracts and may precede other clinical symptoms
Line 24: Line 24:
*[[Inflammatory bowel disease]]
*[[Inflammatory bowel disease]]
*[[Cystic fibrosis]]
*[[Cystic fibrosis]]
*[[Sarcoidosis]], which will cause granuloma formation but shouldn't increase risk of infection
*[[Sarcoidosis]]


==Diagnosis==
==Diagnosis==


*The diagnosis is confirmed with the dihyohodamine-123 (DHR-123) test
*The diagnosis is confirmed with the dihydrohodamine-123 (DHR-123) test


==Management==
==Management==

Latest revision as of 16:56, 2 February 2022

Background

Pathophysiology

  • Defect in NADPH oxidase
  • Therefore unable to generate superoxide radicals required by phagocytes to kill pathogens

Clinical Manifestations

Differential Diagnosis

Diagnosis

  • The diagnosis is confirmed with the dihydrohodamine-123 (DHR-123) test

Management

Further Reading

  • Considerations in the Diagnosis of Chronic Granulomatous Disease. J Pediatric Infect Dis Soc. 2018;7(S1):S6-S11. doi: 10.1093/jpids/piy007